Gantenerumab GRADUATE I and II failed to meet primary clinical endpoints despite amyloid-lowering rationale, reinforcing that target engagement alone does not guarantee clinical translation.

Evidence span

Gantenerumab GRADUATE I and II failed to meet primary clinical endpoints despite amyloid-lowering rationale, reinforcing that target engagement alone does not guarantee clinical translation.

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Early Alzheimer's disease phase 3 trials of gantenerumab.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required